Identification of serum biomarker signatures associated with pancreatic cancer

Cancer Research

Volumn 72, Issue 10, 2012, Pages 2481-2490

  Wingren, Christer ^a   Sandström, Anna ^a   Segersvärd, Ralf ^c   Carlsson, Anders ^a   Andersson, Roland ^b   Löhr, Matthias ^c   Borrebaeck, Carl A K ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; LEPTIN; LYMPHOTOXIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; PROPERDIN; RANTES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE PANCREATITIS; CANCER SCREENING; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PANCREATITIS, CHRONIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84861176020     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2883     Document Type: Article

References (46)

1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
2. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
3. Chu D, Kohlmann W, Adler DG. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP 2010;11:203-12.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
5. Pannala R, Basu A, Petersen GM, Chari ST. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88-95.
6. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81.
7. Galasso D, Carnuccio A, Larghi A. Pancreatic cancer: diagnosis and endoscopic staging. Eur Rev Med Pharmacol Sci 2010;14:375-85.
8. Biankin AV, Kench JG, Dijkman FP, Biankin SA, Henshall SM. Molecular pathogenesis of precursor lesions of pancreatic ductal adenocarcinoma. Pathology 2003;35:14-24. (Pubitemid 36349941)
9. Chen R, Pan S, Aebersold R, Brentnall TA. Proteomics studies of pancreatic cancer. Proteomics Clin Appl 2007;1:1582-91.
10. Duffy MJ, Sturgeon C, Lamerz R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 2010;21:441-7.
11. Fry LC, Monkenmuller K, Malfertheiner P. Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg 2008;393:883-90.
12. Fiedler GM, Leichtle AB, Kase J, Baumann S, Ceglarek U, Felix K, et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer. Clin Cancer Res 2009;15:3812-9.
13. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006;15:442-6. (Pubitemid 43166133)
14. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006;70:255-64. (Pubitemid 44670165)
15. Ingvarsson J, Larsson A, Sj€oholm AG, Truedsson L, Jansson B, Borrebaeck CAK, et al. Design of recombinant antibody microarrays for serum protein profiling: targeting of complement proteins. J Proteome Res 2007;6:3527-36. (Pubitemid 47522744)
16. Wingren C, Ingvarsson J, Dexlin L, Szul D, Borrebaeck CAK. Design of recombinant antibody microarrays for complex proteome analysis: choice of sample labeling-tag and solid support. Proteomics 2007;7: 3055-65. (Pubitemid 47477950)
17. Ingvarsson J, Wingren C, Carlsson A, Ellmark P, Wahren B, Engstr€om G, et al. Detection of pancreatic cancer using antibody microarraybased serum protein profiling. Proteomics 2008;8:2211-19. (Pubitemid 351898027)
18. Carlsson A, Persson O, Ingvarsson J, Widegren B, Salford L, Borrebaeck CAK, et al. Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics Clin Appl 2010;4: 591-602.
19. S€oderlind E, Strandberg L, Jirholt P, Kobayashi N, Alexeiva V, Aberg AM, et al. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 2000;18: 852-6.
20. Borrebaeck CAK, Wingren C. Design of high-density antibody microarrays for disease proteomics: key technological issues. J Proteomics 2009;72:928-35.
21. Borrebaeck CAK, Wingren C. High-throughput proteomics using antibody microarrays: an update. Expert Rev Mol Diagn 2007;7:673-86. (Pubitemid 47547731)
22. Carlsson A, Wingren C, Ingvarsson J, Ellmar P, Baldertorp B, Fern€oM, et al. Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer 2008;44:472-80. (Pubitemid 351179627)
23. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2005;2:416-22. (Pubitemid 43115010)
24. Lohr M. Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol 2006;3:236-7. (Pubitemid 43675015)
25. Ellmark P, Ingvarsson J, Carlsson A, Lundin BS, Wingren C, Borrebaeck CAK. Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays. Mol Cell Proteomics 2006;5: 1638-46. (Pubitemid 44480391)
26. Clark CE, Beatty GL, Vonderheide RH. Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. Cancer Lett 2009;279:1-7.
27. Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, Lohr JM, et al. Pancreatic cancer microenvironment. Int J Cancer 2007;121:699-705. (Pubitemid 47106197)
28. Chechlinska M, Kowalewska M, Nowak R. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 2010;10:2-3.
29. Orchekowski R, Hamelinck D, Li L, Gliwa E, van Brocklin M, Marrero JA, et al. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res 2005;65:11193-202. (Pubitemid 41713391)
30. Gao WM, Kuick R, Orchekowski RP, Misek DE, Qiu J, Greenberg AK, et al. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 2005;5:110.
31. Miller JC, Zhou H, Kwekel J, Cavallo R, Burke J, Butler EB, et al. Antibodymicroarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 2003;3:56-63. (Pubitemid 36151068)
32. Dexlin-Mellby L, Sandstr€om A, Centlow M, Nygren S, Hansson SR, Borrebaeck CAK, et al. Tissue proteomic profiling of preeclamptic placenta tissue using recombinant antibody microarrays. Proteomics - Clin Appl 2010;4:794-807.
33. Carlsson A, Wuttge DM, Ingvarsson J, Bengtsson AA, Sturfelt G, Borrebaeck CA, et al. Serum protein profiling of systemic lupus erythematosus and systemic sclerosis using recombinant antibody microarrays. Mol Cell Proteomics 2011;10:M110.005033.
34. Bellone G, Smirne C, Mauri FA, Tonel E, Carbone A, Buffolino A, et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 2006;55:684-98.
35. Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, Fisher GA, et al. Identification of a biomarker panel using a multiplexed proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Transl Med 2009;7:105.
36. Poch B, Lotspeich E, Ramadani M, Gansauge S, Beger HG, Gansauge F. Systemic immune dysfunction in pancreatic cancer patients. Langenbecks Arch Surg 2007;392:353-8. (Pubitemid 46675798)
37. Wigmore SJ, Fearon KC, Sangster K, Maingay JP, Garden OJ, Ross JA. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol 2002;21: 881-6.
38. Frick VO, Rubie C, Wagner M, Graeber S, Grimm H, Kopp B, et al. Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. Pancreatology 2008;8:488-97.
39. Ungefroren H, Voss M, Bernstorff WV, Schmid A, Kremer B, Kalthoff H. Immunological escape mechanisms in pancreatic carcinoma. Ann N Y Acad Sci 1999;880:243-51. (Pubitemid 29349133)
40. Schmitz-Winnenthal FH, Volk C, Z'graggen K, Galindo L, Nummer D, Ziouta Y, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005;65:10079-87. (Pubitemid 41541490)
41. Chen R, Pan S, Cooke K, Moyes KW, Bronner MP, Goodlett DR, et al. Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 2007; 34:70-9. (Pubitemid 46045723)
42. Yu KH, Rustig AK, Blair IA. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J Proteome Res 2005;4:1742-51. (Pubitemid 41464802)
43. Nakano M, Nakagawa T, Ito T, Kitada T, Hijioka T, Kasahara A, et al. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 2008;122:2301-9. (Pubitemid 351542335)
44. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005;41:2213-36. (Pubitemid 41415597)
45. Rustgi AK. Pancreatic cancer: novel approaches to diagnosis and therapy. Gastroenterology 2005;129:1344-7. (Pubitemid 41446872)
46. Schneider R, Slater EP, Sina M, Habbe N, Fendrich V, Matthai E, et al. German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 2011;10:323-30.